Drug Interactions between betrixaban and lidocaine / menthol / methyl salicylate topical
This report displays the potential drug interactions for the following 2 drugs:
- betrixaban
- lidocaine/menthol/methyl salicylate topical
Interactions between your drugs
methyl salicylate topical betrixaban
Applies to: lidocaine / menthol / methyl salicylate topical and betrixaban
GENERALLY AVOID: Salicylates may be absorbed systemically following topical administration and may potentiate the effects of oral anticoagulants. Salicylates interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X, occasionally increasing the prothrombin time. Altered coagulation parameters and/or bleeding have been reported in patients stabilized on warfarin following the use of topical analgesic preparations containing methyl salicylate.
MANAGEMENT: Patients treated with oral anticoagulants should avoid or limit self-medication with these products. Systemic absorption of topical medication may be increased with frequent applications; use of large quantities or over large areas of skin; use of ointment-based formulations; and use of occlusive dressings or heating pads over application areas. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. Patients should also be counseled to avoid any other over-the-counter salicylate products.
References (2)
- Chan TY (1995) "Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance." Ann Pharmacother, 29, p. 1274-83
- Joss JD, LeBlond RF (2000) "Potentiation of warfarin anticoagulation associated with topical methyl salicylate." Ann Pharmacother, 34, p. 729-33
Drug and food interactions
betrixaban food
Applies to: betrixaban
ADJUST DOSING INTERVAL: Food reduces the oral bioavailability of betrixaban. When administered with a low-fat (900 calories; 20% fat) or high-fat (900 calories; 60% fat) meal, betrixaban peak plasma concentration (Cmax) and systemic exposure (AUC) decreased relative to administration in the fasting state by an average of 70% and 61%, respectively, with the low-fat meal and 50% and 48%, respectively, with the high-fat meal. The effect of food on betrixaban pharmacokinetics could be observed for up to 6 hours after meal intake.
MANAGEMENT: The manufacturer recommends taking betrixaban at the same time each day with food.
References (1)
- (2017) "Product Information. Bevyxxa (betrixaban)." Portola Pharmaceuticals
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.